Welcome to our dedicated page for Arcadia Bioscien news (Ticker: RKDA), a resource for investors and traders seeking the latest updates and insights on Arcadia Bioscien stock.
Arcadia Biosciences, Inc. reports developments tied to its plant-based health and wellness products business, including Zola coconut water and agronomic wheat traits. Company news includes operating and financial results, business highlights, material agreements, shareholder voting matters, and capital-structure actions involving its publicly traded common stock.
Recurring updates also cover governance matters, security-structure disclosures, and other corporate events that affect the company's financing, reporting, and operating profile.
Arcadia Biosciences (Nasdaq: RKDA) reported first quarter 2026 results. Zola coconut water unit volumes rose 18% year-over-year, supported by a price increase, though total revenues declined 8% to $1.1 million.
Total operating expenses climbed to $1.9 million, while SG&A reached the lowest level in company history. Net loss attributable to common stockholders was $4.4 million, versus $2.6 million net income a year earlier, impacted by a $2.9 million warrant inducement loss. Arcadia also received approximately $2.1 million in gross proceeds from exercises of preferred investment options.
Arcadia Biosciences (Nasdaq: RKDA) reported Q4 and full-year 2025 results and business updates on March 26, 2026. The company said it received a termination notice for the proposed Roosevelt Resources business combination and raised approximately $2.1 million from exercise of preferred investment options.
Zola coconut water revenues rose 17% YoY. SG&A expense declined ~27%, net cash used in operating activities fell 49%, Q4 revenue was $0.9M vs $1.2M prior year, and full-year revenue was $4.858M vs $5.045M in 2024. Q4 net loss attributable to common stockholders was $1.336M (Q4 2024: $4.064M).
Arcadia Biosciences (Nasdaq: RKDA) agreed to immediate exercises of certain preferred investment options to purchase up to 808,595 shares at a reduced exercise price of $2.575 per share, generating approximately $2.1 million gross proceeds before fees. In exchange, Arcadia will issue new unregistered preferred investment options to buy up to 1,617,190 shares at an exercise price of $2.325, exercisable immediately and expiring 30 months after the Resale Registration Statement effective date. The offering is expected to close on or about January 12, 2026, with H.C. Wainwright & Co. as placement agent.
Net proceeds are intended for working capital and general corporate purposes.
Arcadia Biosciences (Nasdaq: RKDA) said it received a termination notice from Roosevelt Resources on December 24, 2025, ending the Securities Exchange Agreement dated December 4, 2024 for a proposed business combination.
The company said it will resume evaluating strategic alternatives to create shareholder value. Management noted operational streamlining, reduced operating expenses, growth of the Zola coconut water brand, and avoidance of long-term debt over the past two-and-a-half years. Arcadia also reported it continues to own approximately 2.7 million shares of Above Food Ingredients common stock and stated it believes it is entitled to additional consideration relating to its May 2024 sale of GoodWheat.
Arcadia Biosciences (Nasdaq: RKDA) reported third quarter 2025 results on Nov 7, 2025 showing mixed operating performance and balance sheet activity.
Zola year-to-date revenue rose 26% driven by increased distribution; third-quarter revenues were flat year‑over‑year. Gross profit margins exceeded 30% for the 11th consecutive quarter. Cash declined by $257K to $1.1M. The company recognized a $4.7M credit loss/b) related to an outstanding promissory note and received ~ shares of Above Food Ingredients as partial repayment.
Arcadia Biosciences (NASDAQ:RKDA) reported Q2 2025 financial results, with total revenues increasing 11% year-over-year to $1.46 million, driven by 24% growth in Zola® coconut water sales. The company maintained gross margins above 30% for ten consecutive quarters.
Key developments include receiving 2.7 million shares of Above Food Ingredients (ABVE) stock as partial repayment of a $6 million note receivable from the GoodWheat™ assets sale, and eliminating $1 million in contingent liabilities through an agreement with Bioseed Research India. However, the company recognized a $4.5 million credit loss related to the Above Food note receivable.
Q2 2025 resulted in a net loss of $4.46 million ($3.26 per share), compared to net income of $1.06 million in Q2 2024. The company's pending business combination with Roosevelt Resources continues to progress with an amended Form S-4 registration statement filed.
Arcadia Biosciences (Nasdaq: RKDA), a producer and marketer of plant-based health and wellness products, has scheduled its first quarter 2025 financial results announcement for May 8, 2025.
The company will host a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss their Q1 results and key strategic achievements. Investors and interested parties can participate through two options:
- An audio-only webcast available through the Investors section of Arcadia's website
- Live call participation by registering online to receive a dial-in number and unique PIN
A recorded replay of the conference call will be made available in the Investors Section of the company's website following the event.
Arcadia Biosciences (RKDA) reported strong financial results for Q4 and full-year 2024, with year-over-year revenues growing 56% in Q4 and 13% for the full year. The company's Zola® coconut water brand showed exceptional performance with 124% revenue growth in Q4 and 46% for the full year.
Key developments include a planned business combination with Roosevelt Resources, where Roosevelt partners will own approximately 90% of Arcadia post-merger. The company also completed strategic asset sales, including the $4 million sale of its Resistant Starch Durum trait to Corteva Agriscience and the $4 million sale of GoodWheat brand to Above Food Corp.
Financial highlights show Zola's retail distribution nearly doubled in 2024, contributing to a $611,000 increase in Q4 coconut water revenue. The company reported a net loss of $4.1 million ($2.98 per share) in Q4 2024, compared to $2.8 million ($2.10 per share) in Q4 2023.
Arcadia Biosciences (RKDA), a producer and marketer of innovative, plant-based health and wellness products, has scheduled its fourth quarter and full year 2024 financial results announcement for March 20, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss Q4 and year-end results along with key strategic achievements. Investors can participate through an audio-only webcast available on Arcadia's website or join the live call through registration for a dial-in number and unique PIN.